Business Context and Reporting Period
Company: Propanc Biopharma, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: March 16, 2021
Event: Entry into a Material Definitive Agreement and creation of a direct financial obligation.
Key Financial Metrics and Transaction Details
- Instrument: 8% Convertible Promissory Note.
- Principal Amount: $63,500.
- Net Proceeds: $60,000 (intended for general working capital).
- Transaction Costs: $3,500 paid to the investor for fees and expenses.
- Interest Rate: 8% per annum (payable in cash or shares upon maturity/acceleration).
- Maturity Date: March 16, 2022.
- Conversion Terms:
- Conversion period begins September 12, 2021.
- Conversion price is 65% of the Market Price (35% discount).
- Conversion is restricted if the investor's beneficial ownership exceeds 4.99% of outstanding shares.
- Prepayment Premiums: Ranges from 110% to 129% of the face amount plus accrued interest, depending on the timing of prepayment within the first 180 days.
- Default Penalty: Upon certain events of default, the obligation increases to 150% of the outstanding principal plus accrued interest.
Material Changes and Unusual Items
This filing represents a new debt obligation and potential equity dilution. The filing does not provide comparative financial data (revenue, profit, cash flow) as it is a current report regarding a specific transaction rather than a periodic financial statement. The transaction introduces a variable conversion price mechanism and significant prepayment penalties that differ from standard debt instruments.
Guidance, Risks, and Contingencies
- Use of Proceeds: Management intends to use net proceeds for general working capital purposes.
- Events of Default: Include failure to issue shares upon conversion, insolvency, bankruptcy, failure to maintain OTC listing, restatement of financial statements, or failure to comply with SEC reporting requirements.
- Asset Disposition Restriction: The Company covenants not to sell or dispose of substantially all assets (becoming a "shell company") without investor consent while the Note is outstanding.
- Penalty for Delay: A $1,000 penalty applies if shares are not delivered within three business days of a conversion notice (unless caused by a third party).
- Regulatory Status: The securities were issued in a private placement under Section 4(a)(2) of the Securities Act and/or Regulation D.
Investor Verification Checklist
- Verify the current trading price of the Company's common stock to assess the potential dilution impact of the 35% discount conversion feature.
- Confirm the Company's ability to maintain its listing on an OTC market or equivalent exchange to avoid triggering an event of default.
- Review the Company's cash position to determine if it can meet the 8% interest obligation or the potential 150% default penalty if liquidity issues arise.
- Check for any subsequent filings regarding the actual closing of the transaction (noted as "on or about March 18, 2021") and the issuance of shares.
- Assess the impact of the 4.99% beneficial ownership limitation on the investor's ability to convert the note.